BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 05, 2011
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Toviaz fesoterodine: Phase IV data

Top-line data from the double-blind, U.S. Phase IV Study A0221048 trial in 937 patients with OAB showed that once-daily 4 and 8 mg Toviaz met the primary endpoint of...

Read the full 125 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >